nodes	percent_of_prediction	percent_of_DWPC	metapath
Gliclazide—ALB—Crohn's disease	0.662	1	CbGaD
Gliclazide—ALB—Prednisone—Crohn's disease	0.0254	0.607	CbGbCtD
Gliclazide—CYP2C19—Prednisone—Crohn's disease	0.0165	0.393	CbGbCtD
Gliclazide—ABCC8—penis—Crohn's disease	0.0139	0.41	CbGeAlD
Gliclazide—VEGFA—smooth muscle tissue—Crohn's disease	0.00358	0.105	CbGeAlD
Gliclazide—ALB—gall bladder—Crohn's disease	0.00339	0.0997	CbGeAlD
Gliclazide—VEGFA—mammalian vulva—Crohn's disease	0.00322	0.0948	CbGeAlD
Gliclazide—ABCC8—smooth muscle tissue—Crohn's disease	0.00236	0.0694	CbGeAlD
Gliclazide—KCNJ11—lymphoid tissue—Crohn's disease	0.00205	0.0602	CbGeAlD
Gliclazide—VEGFA—Dexamethasone—Prednisone—Crohn's disease	0.00184	0.5	CbGdCrCtD
Gliclazide—VEGFA—Betamethasone—Prednisone—Crohn's disease	0.00184	0.5	CbGdCrCtD
Gliclazide—VEGFA—Cellular response to hypoxia—RBX1—Crohn's disease	0.00183	0.0352	CbGpPWpGaD
Gliclazide—VEGFA—lymph node—Crohn's disease	0.00161	0.0475	CbGeAlD
Gliclazide—VEGFA—Plexin-D1 Signaling—ITGA4—Crohn's disease	0.0016	0.0309	CbGpPWpGaD
Gliclazide—VEGFA—Cellular response to hypoxia—UBE2D1—Crohn's disease	0.0016	0.0309	CbGpPWpGaD
Gliclazide—Pancreatitis acute—Prednisone—Crohn's disease	0.00157	0.00761	CcSEcCtD
Gliclazide—Jaundice cholestatic—Mesalazine—Crohn's disease	0.00156	0.00755	CcSEcCtD
Gliclazide—Arthropathy—Mesalazine—Crohn's disease	0.00151	0.0073	CcSEcCtD
Gliclazide—Pancytopenia—Mercaptopurine—Crohn's disease	0.0015	0.00729	CcSEcCtD
Gliclazide—Gout—Mesalazine—Crohn's disease	0.00147	0.00711	CcSEcCtD
Gliclazide—Hepatic enzyme increased—Mesalazine—Crohn's disease	0.00145	0.00702	CcSEcCtD
Gliclazide—Colitis—Azathioprine—Crohn's disease	0.00144	0.007	CcSEcCtD
Gliclazide—VEGFA—Hypertrophy Model—IL18—Crohn's disease	0.00143	0.0275	CbGpPWpGaD
Gliclazide—Epigastric discomfort—Prednisone—Crohn's disease	0.00138	0.00668	CcSEcCtD
Gliclazide—VEGFA—Differentiation Pathway—TNFSF11—Crohn's disease	0.00137	0.0264	CbGpPWpGaD
Gliclazide—Vaginal inflammation—Mesalazine—Crohn's disease	0.00137	0.00664	CcSEcCtD
Gliclazide—Neoplasm—Azathioprine—Crohn's disease	0.00136	0.00659	CcSEcCtD
Gliclazide—Melaena—Mesalazine—Crohn's disease	0.00134	0.00648	CcSEcCtD
Gliclazide—Cystitis noninfective—Mesalazine—Crohn's disease	0.00134	0.00648	CcSEcCtD
Gliclazide—Hepatobiliary disease—Mercaptopurine—Crohn's disease	0.00134	0.00647	CcSEcCtD
Gliclazide—VEGFA—Allograft Rejection—LRRK2—Crohn's disease	0.00133	0.0256	CbGpPWpGaD
Gliclazide—Cystitis—Mesalazine—Crohn's disease	0.00132	0.00641	CcSEcCtD
Gliclazide—Colitis—Mesalazine—Crohn's disease	0.00132	0.00637	CcSEcCtD
Gliclazide—Blood urea increased—Mesalazine—Crohn's disease	0.00129	0.00627	CcSEcCtD
Gliclazide—Vaginal infection—Mesalazine—Crohn's disease	0.00129	0.00627	CcSEcCtD
Gliclazide—Neuropathy—Mesalazine—Crohn's disease	0.00129	0.00623	CcSEcCtD
Gliclazide—VEGFA—Signaling events mediated by TCPTP—PTPN2—Crohn's disease	0.00127	0.0244	CbGpPWpGaD
Gliclazide—Hypertriglyceridaemia—Prednisone—Crohn's disease	0.00126	0.00611	CcSEcCtD
Gliclazide—Coma—Mesalazine—Crohn's disease	0.00125	0.00606	CcSEcCtD
Gliclazide—Hepatic function abnormal—Azathioprine—Crohn's disease	0.00125	0.00605	CcSEcCtD
Gliclazide—Bladder pain—Mesalazine—Crohn's disease	0.00124	0.006	CcSEcCtD
Gliclazide—Hepatic failure—Azathioprine—Crohn's disease	0.00121	0.00589	CcSEcCtD
Gliclazide—KCNJ11—lymph node—Crohn's disease	0.00115	0.034	CbGeAlD
Gliclazide—Blood alkaline phosphatase increased—Mesalazine—Crohn's disease	0.00114	0.00554	CcSEcCtD
Gliclazide—Photosensitivity—Mesalazine—Crohn's disease	0.00113	0.00549	CcSEcCtD
Gliclazide—Hypothyroidism—Prednisone—Crohn's disease	0.00113	0.00547	CcSEcCtD
Gliclazide—Gastroenteritis—Mesalazine—Crohn's disease	0.00112	0.00544	CcSEcCtD
Gliclazide—Deafness—Mesalazine—Crohn's disease	0.00111	0.00539	CcSEcCtD
Gliclazide—Hepatic failure—Mesalazine—Crohn's disease	0.00111	0.00536	CcSEcCtD
Gliclazide—Eczema—Mesalazine—Crohn's disease	0.00111	0.00536	CcSEcCtD
Gliclazide—Blood triglycerides increased—Prednisone—Crohn's disease	0.00111	0.00536	CcSEcCtD
Gliclazide—Malnutrition—Mercaptopurine—Crohn's disease	0.0011	0.00535	CcSEcCtD
Gliclazide—Renal failure acute—Mesalazine—Crohn's disease	0.00108	0.00522	CcSEcCtD
Gliclazide—CYP2C19—digestive system—Crohn's disease	0.00107	0.0316	CbGeAlD
Gliclazide—Increased appetite—Mesalazine—Crohn's disease	0.00106	0.00513	CcSEcCtD
Gliclazide—Renal impairment—Mesalazine—Crohn's disease	0.00104	0.00506	CcSEcCtD
Gliclazide—Thirst—Mesalazine—Crohn's disease	0.00104	0.00506	CcSEcCtD
Gliclazide—Hepatomegaly—Prednisone—Crohn's disease	0.00102	0.00496	CcSEcCtD
Gliclazide—Arthritis—Mesalazine—Crohn's disease	0.00102	0.00496	CcSEcCtD
Gliclazide—Anaemia—Mercaptopurine—Crohn's disease	0.00102	0.00494	CcSEcCtD
Gliclazide—VEGFA—Platelet degranulation—F5—Crohn's disease	0.000996	0.0192	CbGpPWpGaD
Gliclazide—Gastrointestinal haemorrhage—Mesalazine—Crohn's disease	0.000994	0.00482	CcSEcCtD
Gliclazide—Osteoarthritis—Mesalazine—Crohn's disease	0.000994	0.00482	CcSEcCtD
Gliclazide—Leukopenia—Mercaptopurine—Crohn's disease	0.000988	0.00479	CcSEcCtD
Gliclazide—Toxic epidermal necrolysis—Azathioprine—Crohn's disease	0.000983	0.00476	CcSEcCtD
Gliclazide—Glaucoma—Prednisone—Crohn's disease	0.000962	0.00466	CcSEcCtD
Gliclazide—VEGFA—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—PTGS2—Crohn's disease	0.000959	0.0185	CbGpPWpGaD
Gliclazide—VEGFA—Response to elevated platelet cytosolic Ca2+—F5—Crohn's disease	0.000949	0.0183	CbGpPWpGaD
Gliclazide—Arthralgia—Mercaptopurine—Crohn's disease	0.000939	0.00455	CcSEcCtD
Gliclazide—Fungal infection—Prednisone—Crohn's disease	0.000939	0.00455	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Mercaptopurine—Crohn's disease	0.000933	0.00452	CcSEcCtD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—CREM—Crohn's disease	0.00093	0.0179	CbGpPWpGaD
Gliclazide—Dry skin—Mesalazine—Crohn's disease	0.000911	0.00442	CcSEcCtD
Gliclazide—Abdominal discomfort—Azathioprine—Crohn's disease	0.000904	0.00438	CcSEcCtD
Gliclazide—VEGFA—Differentiation Pathway—IL3—Crohn's disease	0.000899	0.0173	CbGpPWpGaD
Gliclazide—Pancytopenia—Azathioprine—Crohn's disease	0.000896	0.00434	CcSEcCtD
Gliclazide—Glycosuria—Prednisone—Crohn's disease	0.000895	0.00433	CcSEcCtD
Gliclazide—Thrombocytopenia—Mercaptopurine—Crohn's disease	0.000882	0.00427	CcSEcCtD
Gliclazide—Gastritis—Mesalazine—Crohn's disease	0.00088	0.00426	CcSEcCtD
Gliclazide—Skin disorder—Mercaptopurine—Crohn's disease	0.000875	0.00424	CcSEcCtD
Gliclazide—Abdominal distension—Mesalazine—Crohn's disease	0.000865	0.00419	CcSEcCtD
Gliclazide—Asthma—Mesalazine—Crohn's disease	0.000859	0.00416	CcSEcCtD
Gliclazide—Pneumonia—Azathioprine—Crohn's disease	0.000846	0.0041	CcSEcCtD
Gliclazide—Delirium—Prednisone—Crohn's disease	0.000843	0.00408	CcSEcCtD
Gliclazide—Angina pectoris—Mesalazine—Crohn's disease	0.000837	0.00406	CcSEcCtD
Gliclazide—VEGFA—Hypertrophy Model—IFNG—Crohn's disease	0.000837	0.0161	CbGpPWpGaD
Gliclazide—VEGFA—S1P1 pathway—PTGS2—Crohn's disease	0.000836	0.0161	CbGpPWpGaD
Gliclazide—Stevens-Johnson syndrome—Azathioprine—Crohn's disease	0.000834	0.00404	CcSEcCtD
Gliclazide—CYP2C9—digestive system—Crohn's disease	0.000832	0.0245	CbGeAlD
Gliclazide—VEGFA—Signaling events mediated by VEGFR1 and VEGFR2—PTPN2—Crohn's disease	0.00083	0.016	CbGpPWpGaD
Gliclazide—Bronchitis—Mesalazine—Crohn's disease	0.000826	0.004	CcSEcCtD
Gliclazide—Abdominal discomfort—Mesalazine—Crohn's disease	0.000824	0.00399	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Mercaptopurine—Crohn's disease	0.00082	0.00398	CcSEcCtD
Gliclazide—Pancytopenia—Mesalazine—Crohn's disease	0.000816	0.00395	CcSEcCtD
Gliclazide—Viral infection—Prednisone—Crohn's disease	0.000802	0.00389	CcSEcCtD
Gliclazide—Upper respiratory tract infection—Mesalazine—Crohn's disease	0.000799	0.00387	CcSEcCtD
Gliclazide—Arthropathy—Prednisone—Crohn's disease	0.000797	0.00386	CcSEcCtD
Gliclazide—Hepatobiliary disease—Azathioprine—Crohn's disease	0.000796	0.00386	CcSEcCtD
Gliclazide—Agranulocytosis—Azathioprine—Crohn's disease	0.000785	0.0038	CcSEcCtD
Gliclazide—Photosensitivity reaction—Mesalazine—Crohn's disease	0.000784	0.0038	CcSEcCtD
Gliclazide—Weight increased—Mesalazine—Crohn's disease	0.000782	0.00379	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Mercaptopurine—Crohn's disease	0.000777	0.00377	CcSEcCtD
Gliclazide—Pneumonia—Mesalazine—Crohn's disease	0.000771	0.00373	CcSEcCtD
Gliclazide—Hypercholesterolaemia—Prednisone—Crohn's disease	0.000766	0.00371	CcSEcCtD
Gliclazide—Depression—Mesalazine—Crohn's disease	0.000764	0.0037	CcSEcCtD
Gliclazide—Cataract—Prednisone—Crohn's disease	0.000761	0.00369	CcSEcCtD
Gliclazide—ALB—lymph node—Crohn's disease	0.000761	0.0224	CbGeAlD
Gliclazide—Stevens-Johnson syndrome—Mesalazine—Crohn's disease	0.00076	0.00368	CcSEcCtD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—ZMIZ1—Crohn's disease	0.000754	0.0145	CbGpPWpGaD
Gliclazide—Renal failure—Mesalazine—Crohn's disease	0.000753	0.00365	CcSEcCtD
Gliclazide—Neuropathy peripheral—Mesalazine—Crohn's disease	0.000751	0.00364	CcSEcCtD
Gliclazide—Jaundice—Mesalazine—Crohn's disease	0.000747	0.00362	CcSEcCtD
Gliclazide—Urinary tract infection—Mesalazine—Crohn's disease	0.000745	0.00361	CcSEcCtD
Gliclazide—Conjunctivitis—Mesalazine—Crohn's disease	0.000745	0.00361	CcSEcCtD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—MST1—Crohn's disease	0.000735	0.0142	CbGpPWpGaD
Gliclazide—Sweating—Mesalazine—Crohn's disease	0.000735	0.00356	CcSEcCtD
Gliclazide—Hepatobiliary disease—Mesalazine—Crohn's disease	0.000725	0.00351	CcSEcCtD
Gliclazide—Epistaxis—Mesalazine—Crohn's disease	0.000723	0.0035	CcSEcCtD
Gliclazide—Sinusitis—Mesalazine—Crohn's disease	0.000719	0.00348	CcSEcCtD
Gliclazide—Agranulocytosis—Mesalazine—Crohn's disease	0.000715	0.00346	CcSEcCtD
Gliclazide—VEGFA—Beta1 integrin cell surface interactions—ITGA4—Crohn's disease	0.000714	0.0138	CbGpPWpGaD
Gliclazide—Erythema multiforme—Azathioprine—Crohn's disease	0.000714	0.00346	CcSEcCtD
Gliclazide—VEGFA—S1P3 pathway—JAK2—Crohn's disease	0.000713	0.0137	CbGpPWpGaD
Gliclazide—Body temperature increased—Mercaptopurine—Crohn's disease	0.000712	0.00345	CcSEcCtD
Gliclazide—VEGFA—Allograft Rejection—IL17A—Crohn's disease	0.000698	0.0134	CbGpPWpGaD
Gliclazide—Rhinitis—Mesalazine—Crohn's disease	0.00069	0.00334	CcSEcCtD
Gliclazide—Hepatitis—Mesalazine—Crohn's disease	0.000688	0.00333	CcSEcCtD
Gliclazide—Pharyngitis—Mesalazine—Crohn's disease	0.000683	0.00331	CcSEcCtD
Gliclazide—Neuropathy—Prednisone—Crohn's disease	0.00068	0.0033	CcSEcCtD
Gliclazide—Oedema peripheral—Mesalazine—Crohn's disease	0.000678	0.00328	CcSEcCtD
Gliclazide—Chills—Azathioprine—Crohn's disease	0.000678	0.00328	CcSEcCtD
Gliclazide—Arrhythmia—Azathioprine—Crohn's disease	0.000675	0.00327	CcSEcCtD
Gliclazide—Hypersensitivity—Mercaptopurine—Crohn's disease	0.000663	0.00321	CcSEcCtD
Gliclazide—Oesophagitis—Prednisone—Crohn's disease	0.000662	0.00321	CcSEcCtD
Gliclazide—Erythema multiforme—Mesalazine—Crohn's disease	0.00065	0.00315	CcSEcCtD
Gliclazide—VEGFA—Allograft Rejection—IL12B—Crohn's disease	0.000648	0.0125	CbGpPWpGaD
Gliclazide—Eye disorder—Mesalazine—Crohn's disease	0.000643	0.00311	CcSEcCtD
Gliclazide—Tinnitus—Mesalazine—Crohn's disease	0.000641	0.00311	CcSEcCtD
Gliclazide—Chills—Mesalazine—Crohn's disease	0.000617	0.00299	CcSEcCtD
Gliclazide—Diarrhoea—Mercaptopurine—Crohn's disease	0.000616	0.00299	CcSEcCtD
Gliclazide—Ill-defined disorder—Azathioprine—Crohn's disease	0.00061	0.00296	CcSEcCtD
Gliclazide—Thrombophlebitis—Prednisone—Crohn's disease	0.000608	0.00294	CcSEcCtD
Gliclazide—Anaemia—Azathioprine—Crohn's disease	0.000608	0.00294	CcSEcCtD
Gliclazide—Mental disorder—Mesalazine—Crohn's disease	0.000603	0.00292	CcSEcCtD
Gliclazide—Erythema—Mesalazine—Crohn's disease	0.000599	0.0029	CcSEcCtD
Gliclazide—Malaise—Azathioprine—Crohn's disease	0.000593	0.00287	CcSEcCtD
Gliclazide—Flatulence—Mesalazine—Crohn's disease	0.00059	0.00286	CcSEcCtD
Gliclazide—Leukopenia—Azathioprine—Crohn's disease	0.000588	0.00285	CcSEcCtD
Gliclazide—Tension—Mesalazine—Crohn's disease	0.000588	0.00285	CcSEcCtD
Gliclazide—VEGFA—VEGFR2 mediated cell proliferation—TYK2—Crohn's disease	0.000584	0.0113	CbGpPWpGaD
Gliclazide—Nervousness—Mesalazine—Crohn's disease	0.000582	0.00282	CcSEcCtD
Gliclazide—Back pain—Mesalazine—Crohn's disease	0.000579	0.00281	CcSEcCtD
Gliclazide—Vomiting—Mercaptopurine—Crohn's disease	0.000573	0.00277	CcSEcCtD
Gliclazide—Injury—Prednisone—Crohn's disease	0.000572	0.00277	CcSEcCtD
Gliclazide—Rash—Mercaptopurine—Crohn's disease	0.000568	0.00275	CcSEcCtD
Gliclazide—Dermatitis—Mercaptopurine—Crohn's disease	0.000567	0.00275	CcSEcCtD
Gliclazide—Tremor—Mesalazine—Crohn's disease	0.000561	0.00272	CcSEcCtD
Gliclazide—Increased appetite—Prednisone—Crohn's disease	0.00056	0.00271	CcSEcCtD
Gliclazide—Myalgia—Azathioprine—Crohn's disease	0.00056	0.00271	CcSEcCtD
Gliclazide—Arthralgia—Azathioprine—Crohn's disease	0.00056	0.00271	CcSEcCtD
Gliclazide—VEGFA—VEGFR2 mediated cell proliferation—JAK2—Crohn's disease	0.000558	0.0107	CbGpPWpGaD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—Crohn's disease	0.000556	0.00269	CcSEcCtD
Gliclazide—Ill-defined disorder—Mesalazine—Crohn's disease	0.000556	0.00269	CcSEcCtD
Gliclazide—Anaemia—Mesalazine—Crohn's disease	0.000553	0.00268	CcSEcCtD
Gliclazide—Discomfort—Azathioprine—Crohn's disease	0.000553	0.00268	CcSEcCtD
Gliclazide—VEGFA—Bladder Cancer—CXCL8—Crohn's disease	0.000548	0.0106	CbGpPWpGaD
Gliclazide—Angioedema—Mesalazine—Crohn's disease	0.000547	0.00265	CcSEcCtD
Gliclazide—VEGFA—SHP2 signaling—IL2RA—Crohn's disease	0.000541	0.0104	CbGpPWpGaD
Gliclazide—Malaise—Mesalazine—Crohn's disease	0.00054	0.00262	CcSEcCtD
Gliclazide—Cardiac failure—Prednisone—Crohn's disease	0.000539	0.00261	CcSEcCtD
Gliclazide—Leukopenia—Mesalazine—Crohn's disease	0.000536	0.0026	CcSEcCtD
Gliclazide—Nausea—Mercaptopurine—Crohn's disease	0.000535	0.00259	CcSEcCtD
Gliclazide—ABCC8—FOXA2 and FOXA3 transcription factor networks—ALB—Crohn's disease	0.000534	0.0103	CbGpPWpGaD
Gliclazide—Infection—Azathioprine—Crohn's disease	0.000533	0.00258	CcSEcCtD
Gliclazide—KCNJ11—Type II diabetes mellitus—TNF—Crohn's disease	0.000533	0.0103	CbGpPWpGaD
Gliclazide—Palpitations—Mesalazine—Crohn's disease	0.000529	0.00256	CcSEcCtD
Gliclazide—VEGFA—HIF-1-alpha transcription factor network—SMAD3—Crohn's disease	0.000527	0.0102	CbGpPWpGaD
Gliclazide—Loss of consciousness—Mesalazine—Crohn's disease	0.000526	0.00255	CcSEcCtD
Gliclazide—Gastrointestinal haemorrhage—Prednisone—Crohn's disease	0.000526	0.00255	CcSEcCtD
Gliclazide—Osteoarthritis—Prednisone—Crohn's disease	0.000526	0.00255	CcSEcCtD
Gliclazide—Thrombocytopenia—Azathioprine—Crohn's disease	0.000525	0.00255	CcSEcCtD
Gliclazide—Cough—Mesalazine—Crohn's disease	0.000523	0.00253	CcSEcCtD
Gliclazide—Skin disorder—Azathioprine—Crohn's disease	0.000521	0.00253	CcSEcCtD
Gliclazide—KCNJ11—FOXA2 and FOXA3 transcription factor networks—ALB—Crohn's disease	0.000518	0.00998	CbGpPWpGaD
Gliclazide—Hypertension—Mesalazine—Crohn's disease	0.000517	0.00251	CcSEcCtD
Gliclazide—Chest pain—Mesalazine—Crohn's disease	0.00051	0.00247	CcSEcCtD
Gliclazide—Arthralgia—Mesalazine—Crohn's disease	0.00051	0.00247	CcSEcCtD
Gliclazide—Myalgia—Mesalazine—Crohn's disease	0.00051	0.00247	CcSEcCtD
Gliclazide—Anxiety—Mesalazine—Crohn's disease	0.000508	0.00246	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Mesalazine—Crohn's disease	0.000506	0.00245	CcSEcCtD
Gliclazide—Discomfort—Mesalazine—Crohn's disease	0.000504	0.00244	CcSEcCtD
Gliclazide—Hypotension—Azathioprine—Crohn's disease	0.000501	0.00243	CcSEcCtD
Gliclazide—Dry mouth—Mesalazine—Crohn's disease	0.000499	0.00242	CcSEcCtD
Gliclazide—Confusional state—Mesalazine—Crohn's disease	0.000493	0.00239	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Azathioprine—Crohn's disease	0.000489	0.00237	CcSEcCtD
Gliclazide—Infection—Mesalazine—Crohn's disease	0.000486	0.00235	CcSEcCtD
Gliclazide—Dry skin—Prednisone—Crohn's disease	0.000482	0.00234	CcSEcCtD
Gliclazide—Nervous system disorder—Mesalazine—Crohn's disease	0.000479	0.00232	CcSEcCtD
Gliclazide—Thrombocytopenia—Mesalazine—Crohn's disease	0.000478	0.00232	CcSEcCtD
Gliclazide—Tachycardia—Mesalazine—Crohn's disease	0.000477	0.00231	CcSEcCtD
Gliclazide—Skin disorder—Mesalazine—Crohn's disease	0.000475	0.0023	CcSEcCtD
Gliclazide—VEGFA—Allograft Rejection—IL10—Crohn's disease	0.000474	0.00914	CbGpPWpGaD
Gliclazide—Hyperhidrosis—Mesalazine—Crohn's disease	0.000472	0.00229	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Azathioprine—Crohn's disease	0.000463	0.00224	CcSEcCtD
Gliclazide—Abdominal distension—Prednisone—Crohn's disease	0.000458	0.00222	CcSEcCtD
Gliclazide—Hypotension—Mesalazine—Crohn's disease	0.000457	0.00221	CcSEcCtD
Gliclazide—CYP2C19—Arachidonic acid metabolism—GPX4—Crohn's disease	0.000454	0.00875	CbGpPWpGaD
Gliclazide—Musculoskeletal discomfort—Mesalazine—Crohn's disease	0.000445	0.00216	CcSEcCtD
Gliclazide—Feeling abnormal—Azathioprine—Crohn's disease	0.000442	0.00214	CcSEcCtD
Gliclazide—Insomnia—Mesalazine—Crohn's disease	0.000442	0.00214	CcSEcCtD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—F5—Crohn's disease	0.000442	0.00852	CbGpPWpGaD
Gliclazide—Paraesthesia—Mesalazine—Crohn's disease	0.000439	0.00213	CcSEcCtD
Gliclazide—Gastrointestinal pain—Azathioprine—Crohn's disease	0.000439	0.00213	CcSEcCtD
Gliclazide—Dyspnoea—Mesalazine—Crohn's disease	0.000436	0.00211	CcSEcCtD
Gliclazide—Somnolence—Mesalazine—Crohn's disease	0.000434	0.00211	CcSEcCtD
Gliclazide—Dyspepsia—Mesalazine—Crohn's disease	0.00043	0.00208	CcSEcCtD
Gliclazide—Body temperature increased—Azathioprine—Crohn's disease	0.000424	0.00206	CcSEcCtD
Gliclazide—Abdominal pain—Azathioprine—Crohn's disease	0.000424	0.00206	CcSEcCtD
Gliclazide—VEGFA—Allograft Rejection—IL2RA—Crohn's disease	0.000423	0.00814	CbGpPWpGaD
Gliclazide—Gastrointestinal disorder—Mesalazine—Crohn's disease	0.000422	0.00204	CcSEcCtD
Gliclazide—Fatigue—Mesalazine—Crohn's disease	0.000421	0.00204	CcSEcCtD
Gliclazide—Erectile dysfunction—Prednisone—Crohn's disease	0.000419	0.00203	CcSEcCtD
Gliclazide—Pain—Mesalazine—Crohn's disease	0.000418	0.00202	CcSEcCtD
Gliclazide—Constipation—Mesalazine—Crohn's disease	0.000418	0.00202	CcSEcCtD
Gliclazide—CYP2C9—Arachidonic acid metabolism—GPX4—Crohn's disease	0.000414	0.00798	CbGpPWpGaD
Gliclazide—Weight increased—Prednisone—Crohn's disease	0.000414	0.00201	CcSEcCtD
Gliclazide—VEGFA—Aryl Hydrocarbon Receptor—PTGS2—Crohn's disease	0.000412	0.00794	CbGpPWpGaD
Gliclazide—Hyperglycaemia—Prednisone—Crohn's disease	0.00041	0.00199	CcSEcCtD
Gliclazide—ALB—Folate Metabolism—GPX4—Crohn's disease	0.000405	0.00781	CbGpPWpGaD
Gliclazide—Depression—Prednisone—Crohn's disease	0.000404	0.00196	CcSEcCtD
Gliclazide—Feeling abnormal—Mesalazine—Crohn's disease	0.000403	0.00195	CcSEcCtD
Gliclazide—Acute coronary syndrome—Prednisone—Crohn's disease	0.0004	0.00194	CcSEcCtD
Gliclazide—Gastrointestinal pain—Mesalazine—Crohn's disease	0.0004	0.00194	CcSEcCtD
Gliclazide—Myocardial infarction—Prednisone—Crohn's disease	0.000397	0.00193	CcSEcCtD
Gliclazide—Neuropathy peripheral—Prednisone—Crohn's disease	0.000397	0.00193	CcSEcCtD
Gliclazide—Hypersensitivity—Azathioprine—Crohn's disease	0.000395	0.00192	CcSEcCtD
Gliclazide—Urticaria—Mesalazine—Crohn's disease	0.000388	0.00188	CcSEcCtD
Gliclazide—Abdominal pain—Mesalazine—Crohn's disease	0.000386	0.00187	CcSEcCtD
Gliclazide—Body temperature increased—Mesalazine—Crohn's disease	0.000386	0.00187	CcSEcCtD
Gliclazide—ALB—Vitamin B12 Metabolism—MPO—Crohn's disease	0.00038	0.00732	CbGpPWpGaD
Gliclazide—Bradycardia—Prednisone—Crohn's disease	0.000371	0.0018	CcSEcCtD
Gliclazide—Diarrhoea—Azathioprine—Crohn's disease	0.000367	0.00178	CcSEcCtD
Gliclazide—VEGFA—SHP2 signaling—JAK2—Crohn's disease	0.000364	0.00701	CbGpPWpGaD
Gliclazide—Hypersensitivity—Mesalazine—Crohn's disease	0.00036	0.00174	CcSEcCtD
Gliclazide—VEGFA—Signaling events mediated by TCPTP—STAT3—Crohn's disease	0.000359	0.00693	CbGpPWpGaD
Gliclazide—VEGFA—SHP2 signaling—IFNG—Crohn's disease	0.000357	0.00688	CbGpPWpGaD
Gliclazide—Dizziness—Azathioprine—Crohn's disease	0.000355	0.00172	CcSEcCtD
Gliclazide—ALB—Platelet degranulation—F5—Crohn's disease	0.000352	0.00678	CbGpPWpGaD
Gliclazide—Asthenia—Mesalazine—Crohn's disease	0.000351	0.0017	CcSEcCtD
Gliclazide—VEGFA—Oncostatin M Signaling Pathway—TYK2—Crohn's disease	0.000348	0.00671	CbGpPWpGaD
Gliclazide—Pruritus—Mesalazine—Crohn's disease	0.000346	0.00168	CcSEcCtD
Gliclazide—Vomiting—Azathioprine—Crohn's disease	0.000341	0.00165	CcSEcCtD
Gliclazide—Eye disorder—Prednisone—Crohn's disease	0.00034	0.00165	CcSEcCtD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—TAB1—Crohn's disease	0.00034	0.00655	CbGpPWpGaD
Gliclazide—Rash—Azathioprine—Crohn's disease	0.000338	0.00164	CcSEcCtD
Gliclazide—Dermatitis—Azathioprine—Crohn's disease	0.000338	0.00164	CcSEcCtD
Gliclazide—Flushing—Prednisone—Crohn's disease	0.000338	0.00164	CcSEcCtD
Gliclazide—Headache—Azathioprine—Crohn's disease	0.000336	0.00163	CcSEcCtD
Gliclazide—ALB—Response to elevated platelet cytosolic Ca2+—F5—Crohn's disease	0.000335	0.00645	CbGpPWpGaD
Gliclazide—Diarrhoea—Mesalazine—Crohn's disease	0.000334	0.00162	CcSEcCtD
Gliclazide—VEGFA—Oncostatin M Signaling Pathway—JAK2—Crohn's disease	0.000332	0.0064	CbGpPWpGaD
Gliclazide—Arrhythmia—Prednisone—Crohn's disease	0.000325	0.00158	CcSEcCtD
Gliclazide—Dizziness—Mesalazine—Crohn's disease	0.000323	0.00157	CcSEcCtD
Gliclazide—ALB—Selenium Micronutrient Network—GPX4—Crohn's disease	0.000322	0.0062	CbGpPWpGaD
Gliclazide—Mental disorder—Prednisone—Crohn's disease	0.000319	0.00154	CcSEcCtD
Gliclazide—Nausea—Azathioprine—Crohn's disease	0.000319	0.00154	CcSEcCtD
Gliclazide—Malnutrition—Prednisone—Crohn's disease	0.000317	0.00154	CcSEcCtD
Gliclazide—Erythema—Prednisone—Crohn's disease	0.000317	0.00154	CcSEcCtD
Gliclazide—Vomiting—Mesalazine—Crohn's disease	0.000311	0.00151	CcSEcCtD
Gliclazide—ALB—Folate Metabolism—MPO—Crohn's disease	0.000309	0.00595	CbGpPWpGaD
Gliclazide—Rash—Mesalazine—Crohn's disease	0.000308	0.00149	CcSEcCtD
Gliclazide—Dermatitis—Mesalazine—Crohn's disease	0.000308	0.00149	CcSEcCtD
Gliclazide—VEGFA—Focal Adhesion—ITGA4—Crohn's disease	0.000307	0.00591	CbGpPWpGaD
Gliclazide—Headache—Mesalazine—Crohn's disease	0.000306	0.00148	CcSEcCtD
Gliclazide—VEGFA—Platelet degranulation—ALB—Crohn's disease	0.000302	0.00583	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—IL3—Crohn's disease	0.000298	0.00574	CbGpPWpGaD
Gliclazide—Ill-defined disorder—Prednisone—Crohn's disease	0.000294	0.00142	CcSEcCtD
Gliclazide—Anaemia—Prednisone—Crohn's disease	0.000293	0.00142	CcSEcCtD
Gliclazide—ABCC8—Transmembrane transport of small molecules—SLC22A4—Crohn's disease	0.000292	0.00563	CbGpPWpGaD
Gliclazide—ABCC8—Transmembrane transport of small molecules—SLC22A5—Crohn's disease	0.000292	0.00563	CbGpPWpGaD
Gliclazide—Agitation—Prednisone—Crohn's disease	0.000291	0.00141	CcSEcCtD
Gliclazide—Nausea—Mesalazine—Crohn's disease	0.00029	0.00141	CcSEcCtD
Gliclazide—Angioedema—Prednisone—Crohn's disease	0.000289	0.0014	CcSEcCtD
Gliclazide—VEGFA—Response to elevated platelet cytosolic Ca2+—ALB—Crohn's disease	0.000288	0.00555	CbGpPWpGaD
Gliclazide—VEGFA—VEGFR2 mediated cell proliferation—IL6—Crohn's disease	0.000286	0.00551	CbGpPWpGaD
Gliclazide—Malaise—Prednisone—Crohn's disease	0.000286	0.00138	CcSEcCtD
Gliclazide—VEGFA—Allograft Rejection—IFNG—Crohn's disease	0.000279	0.00537	CbGpPWpGaD
Gliclazide—Loss of consciousness—Prednisone—Crohn's disease	0.000278	0.00135	CcSEcCtD
Gliclazide—VEGFA—Aryl Hydrocarbon Receptor—TNF—Crohn's disease	0.000278	0.00536	CbGpPWpGaD
Gliclazide—VEGFA—Cellular responses to stress—RBX1—Crohn's disease	0.000277	0.00534	CbGpPWpGaD
Gliclazide—VEGFA—Cellular responses to stress—HSPA1B—Crohn's disease	0.000277	0.00534	CbGpPWpGaD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—IL10—Crohn's disease	0.000275	0.0053	CbGpPWpGaD
Gliclazide—Convulsion—Prednisone—Crohn's disease	0.000274	0.00133	CcSEcCtD
Gliclazide—Hypertension—Prednisone—Crohn's disease	0.000274	0.00133	CcSEcCtD
Gliclazide—Arthralgia—Prednisone—Crohn's disease	0.00027	0.00131	CcSEcCtD
Gliclazide—Myalgia—Prednisone—Crohn's disease	0.00027	0.00131	CcSEcCtD
Gliclazide—Anxiety—Prednisone—Crohn's disease	0.000269	0.0013	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—Crohn's disease	0.000268	0.0013	CcSEcCtD
Gliclazide—Discomfort—Prednisone—Crohn's disease	0.000266	0.00129	CcSEcCtD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—IL3—Crohn's disease	0.000265	0.00511	CbGpPWpGaD
Gliclazide—VEGFA—Allograft Rejection—CXCL8—Crohn's disease	0.000259	0.005	CbGpPWpGaD
Gliclazide—Infection—Prednisone—Crohn's disease	0.000257	0.00124	CcSEcCtD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—RASGRP1—Crohn's disease	0.000256	0.00494	CbGpPWpGaD
Gliclazide—Nervous system disorder—Prednisone—Crohn's disease	0.000254	0.00123	CcSEcCtD
Gliclazide—Tachycardia—Prednisone—Crohn's disease	0.000252	0.00122	CcSEcCtD
Gliclazide—Skin disorder—Prednisone—Crohn's disease	0.000251	0.00122	CcSEcCtD
Gliclazide—Hyperhidrosis—Prednisone—Crohn's disease	0.00025	0.00121	CcSEcCtD
Gliclazide—VEGFA—Allograft Rejection—IL1B—Crohn's disease	0.000249	0.00479	CbGpPWpGaD
Gliclazide—ALB—Selenium Micronutrient Network—MPO—Crohn's disease	0.000245	0.00473	CbGpPWpGaD
Gliclazide—VEGFA—Oncostatin M Signaling Pathway—STAT3—Crohn's disease	0.000244	0.0047	CbGpPWpGaD
Gliclazide—VEGFA—Cellular responses to stress—UBE2D1—Crohn's disease	0.000243	0.00468	CbGpPWpGaD
Gliclazide—Musculoskeletal discomfort—Prednisone—Crohn's disease	0.000236	0.00114	CcSEcCtD
Gliclazide—Insomnia—Prednisone—Crohn's disease	0.000234	0.00113	CcSEcCtD
Gliclazide—VEGFA—VEGFA-VEGFR2 Pathway—TYK2—Crohn's disease	0.000234	0.0045	CbGpPWpGaD
Gliclazide—Paraesthesia—Prednisone—Crohn's disease	0.000232	0.00113	CcSEcCtD
Gliclazide—VEGFA—Hemostasis—F5—Crohn's disease	0.000228	0.00439	CbGpPWpGaD
Gliclazide—Dyspepsia—Prednisone—Crohn's disease	0.000228	0.0011	CcSEcCtD
Gliclazide—Fatigue—Prednisone—Crohn's disease	0.000223	0.00108	CcSEcCtD
Gliclazide—VEGFA—VEGFA-VEGFR2 Pathway—JAK2—Crohn's disease	0.000223	0.00429	CbGpPWpGaD
Gliclazide—Constipation—Prednisone—Crohn's disease	0.000221	0.00107	CcSEcCtD
Gliclazide—VEGFA—Signaling by VEGF—TYK2—Crohn's disease	0.00022	0.00425	CbGpPWpGaD
Gliclazide—VEGFA—Differentiation Pathway—IL6—Crohn's disease	0.000217	0.00418	CbGpPWpGaD
Gliclazide—Feeling abnormal—Prednisone—Crohn's disease	0.000213	0.00103	CcSEcCtD
Gliclazide—Gastrointestinal pain—Prednisone—Crohn's disease	0.000211	0.00102	CcSEcCtD
Gliclazide—VEGFA—Signaling by VEGF—JAK2—Crohn's disease	0.00021	0.00405	CbGpPWpGaD
Gliclazide—ABCC8—Transmembrane transport of small molecules—GCKR—Crohn's disease	0.000206	0.00397	CbGpPWpGaD
Gliclazide—Urticaria—Prednisone—Crohn's disease	0.000205	0.000995	CcSEcCtD
Gliclazide—Abdominal pain—Prednisone—Crohn's disease	0.000204	0.00099	CcSEcCtD
Gliclazide—Body temperature increased—Prednisone—Crohn's disease	0.000204	0.00099	CcSEcCtD
Gliclazide—ALB—Vitamin B12 Metabolism—CRP—Crohn's disease	0.0002	0.00385	CbGpPWpGaD
Gliclazide—Hypersensitivity—Prednisone—Crohn's disease	0.000191	0.000923	CcSEcCtD
Gliclazide—VEGFA—SHP2 signaling—IL6—Crohn's disease	0.000186	0.00359	CbGpPWpGaD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—IL2RA—Crohn's disease	0.000186	0.00358	CbGpPWpGaD
Gliclazide—Asthenia—Prednisone—Crohn's disease	0.000186	0.000899	CcSEcCtD
Gliclazide—ALB—SLC-mediated transmembrane transport—SLC22A5—Crohn's disease	0.000185	0.00357	CbGpPWpGaD
Gliclazide—ALB—SLC-mediated transmembrane transport—SLC22A4—Crohn's disease	0.000185	0.00357	CbGpPWpGaD
Gliclazide—ALB—Vitamin B12 Metabolism—ICAM1—Crohn's disease	0.000184	0.00354	CbGpPWpGaD
Gliclazide—Pruritus—Prednisone—Crohn's disease	0.000183	0.000886	CcSEcCtD
Gliclazide—ABCC8—Transmembrane transport of small molecules—SLC11A1—Crohn's disease	0.000182	0.00351	CbGpPWpGaD
Gliclazide—VEGFA—Allograft Rejection—TNF—Crohn's disease	0.00018	0.00348	CbGpPWpGaD
Gliclazide—Diarrhoea—Prednisone—Crohn's disease	0.000177	0.000857	CcSEcCtD
Gliclazide—Dizziness—Prednisone—Crohn's disease	0.000171	0.000829	CcSEcCtD
Gliclazide—CYP2C19—Metapathway biotransformation—GPX4—Crohn's disease	0.000167	0.00321	CbGpPWpGaD
Gliclazide—Vomiting—Prednisone—Crohn's disease	0.000164	0.000797	CcSEcCtD
Gliclazide—Rash—Prednisone—Crohn's disease	0.000163	0.00079	CcSEcCtD
Gliclazide—Dermatitis—Prednisone—Crohn's disease	0.000163	0.000789	CcSEcCtD
Gliclazide—ALB—Folate Metabolism—CRP—Crohn's disease	0.000162	0.00313	CbGpPWpGaD
Gliclazide—Headache—Prednisone—Crohn's disease	0.000162	0.000785	CcSEcCtD
Gliclazide—ABCC8—Metabolism—PLA2G4F—Crohn's disease	0.000161	0.0031	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PLA2G4F—Crohn's disease	0.000156	0.00301	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—F5—Crohn's disease	0.000156	0.00301	CbGpPWpGaD
Gliclazide—Nausea—Prednisone—Crohn's disease	0.000154	0.000744	CcSEcCtD
Gliclazide—CYP2C9—Metapathway biotransformation—GPX4—Crohn's disease	0.000152	0.00293	CbGpPWpGaD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—CXCL8—Crohn's disease	0.00015	0.0029	CbGpPWpGaD
Gliclazide—ALB—Folate Metabolism—ICAM1—Crohn's disease	0.000149	0.00288	CbGpPWpGaD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—IL1B—Crohn's disease	0.000144	0.00278	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—ACKR2—Crohn's disease	0.000142	0.00273	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—ITGA4—Crohn's disease	0.00014	0.0027	CbGpPWpGaD
Gliclazide—ALB—Vitamin B12 Metabolism—IFNG—Crohn's disease	0.00014	0.00269	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—MTMR3—Crohn's disease	0.000137	0.00264	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—IL3—Crohn's disease	0.000137	0.00263	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MLN—Crohn's disease	0.000134	0.00259	CbGpPWpGaD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—ALB—Crohn's disease	0.000134	0.00259	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—MTMR3—Crohn's disease	0.000133	0.00256	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—RASGRP1—Crohn's disease	0.000132	0.00255	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—PTGS2—Crohn's disease	0.000132	0.00254	CbGpPWpGaD
Gliclazide—ALB—SLC-mediated transmembrane transport—GCKR—Crohn's disease	0.000131	0.00252	CbGpPWpGaD
Gliclazide—ALB—Selenium Micronutrient Network—CRP—Crohn's disease	0.000129	0.00249	CbGpPWpGaD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—JAK2—Crohn's disease	0.000125	0.0024	CbGpPWpGaD
Gliclazide—ALB—Vitamin B12 Metabolism—IL1B—Crohn's disease	0.000125	0.0024	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—TAGAP—Crohn's disease	0.000123	0.00237	CbGpPWpGaD
Gliclazide—CYP2C19—Arachidonic acid metabolism—PTGS2—Crohn's disease	0.000122	0.00235	CbGpPWpGaD
Gliclazide—ALB—Selenium Micronutrient Network—ICAM1—Crohn's disease	0.000119	0.00229	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PLA2G4F—Crohn's disease	0.000117	0.00225	CbGpPWpGaD
Gliclazide—ALB—SLC-mediated transmembrane transport—SLC11A1—Crohn's disease	0.000115	0.00223	CbGpPWpGaD
Gliclazide—VEGFA—VEGFA-VEGFR2 Pathway—IL6—Crohn's disease	0.000114	0.0022	CbGpPWpGaD
Gliclazide—ALB—Folate Metabolism—IFNG—Crohn's disease	0.000114	0.00219	CbGpPWpGaD
Gliclazide—CYP2C9—Arachidonic acid metabolism—PTGS2—Crohn's disease	0.000111	0.00215	CbGpPWpGaD
Gliclazide—VEGFA—Signaling by VEGF—IL6—Crohn's disease	0.000108	0.00208	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—RSPO3—Crohn's disease	0.000107	0.00207	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—FADS1—Crohn's disease	0.000107	0.00205	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—SMAD3—Crohn's disease	0.000105	0.00203	CbGpPWpGaD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—TNF—Crohn's disease	0.000105	0.00202	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PLA2G4F—Crohn's disease	0.000105	0.00202	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—FADS1—Crohn's disease	0.000103	0.00199	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—SEL1L—Crohn's disease	0.000102	0.00196	CbGpPWpGaD
Gliclazide—ALB—Folate Metabolism—IL1B—Crohn's disease	0.000101	0.00195	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—GPX4—Crohn's disease	9.98e-05	0.00192	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—MTMR3—Crohn's disease	9.91e-05	0.00191	CbGpPWpGaD
Gliclazide—VEGFA—Cellular responses to stress—CXCL8—Crohn's disease	9.87e-05	0.0019	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—GPX4—Crohn's disease	9.68e-05	0.00187	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—GCKR—Crohn's disease	9.64e-05	0.00186	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—TYK2—Crohn's disease	9.63e-05	0.00186	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—IL2RA—Crohn's disease	9.57e-05	0.00184	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PLA2G4F—Crohn's disease	9.54e-05	0.00184	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—SLC22A5—Crohn's disease	9.42e-05	0.00182	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—SLC22A4—Crohn's disease	9.42e-05	0.00182	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—GCKR—Crohn's disease	9.35e-05	0.0018	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—IL3—Crohn's disease	9.35e-05	0.0018	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CCR9—Crohn's disease	9.32e-05	0.0018	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—JAK2—Crohn's disease	9.18e-05	0.00177	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—RASGRP1—Crohn's disease	9.04e-05	0.00174	CbGpPWpGaD
Gliclazide—ALB—Vitamin B12 Metabolism—TNF—Crohn's disease	9.04e-05	0.00174	CbGpPWpGaD
Gliclazide—ALB—Selenium Micronutrient Network—IFNG—Crohn's disease	9.03e-05	0.00174	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—TNF—Crohn's disease	8.9e-05	0.00172	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—MTMR3—Crohn's disease	8.89e-05	0.00171	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—GPR65—Crohn's disease	8.66e-05	0.00167	CbGpPWpGaD
Gliclazide—ALB—Selenium Micronutrient Network—PTGS2—Crohn's disease	8.65e-05	0.00167	CbGpPWpGaD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—IL6—Crohn's disease	8.45e-05	0.00163	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—MTMR3—Crohn's disease	8.11e-05	0.00156	CbGpPWpGaD
Gliclazide—ALB—Selenium Micronutrient Network—IL1B—Crohn's disease	8.05e-05	0.00155	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—F5—Crohn's disease	8.04e-05	0.00155	CbGpPWpGaD
Gliclazide—VEGFA—Cellular responses to stress—STAT3—Crohn's disease	7.94e-05	0.00153	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—FADS1—Crohn's disease	7.72e-05	0.00149	CbGpPWpGaD
Gliclazide—ALB—Folate Metabolism—TNF—Crohn's disease	7.35e-05	0.00142	CbGpPWpGaD
Gliclazide—ALB—Vitamin B12 Metabolism—IL6—Crohn's disease	7.29e-05	0.00141	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—GPX4—Crohn's disease	7.23e-05	0.00139	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—FADS1—Crohn's disease	6.93e-05	0.00134	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—ALB—Crohn's disease	6.92e-05	0.00133	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—TYK2—Crohn's disease	6.87e-05	0.00132	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—GCKR—Crohn's disease	6.64e-05	0.00128	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—JAK2—Crohn's disease	6.55e-05	0.00126	CbGpPWpGaD
Gliclazide—ABCC8—Transmembrane transport of small molecules—ALB—Crohn's disease	6.55e-05	0.00126	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—IL2RA—Crohn's disease	6.55e-05	0.00126	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—GPX4—Crohn's disease	6.49e-05	0.00125	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—JAK2—Crohn's disease	6.43e-05	0.00124	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—FADS1—Crohn's disease	6.32e-05	0.00122	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CCR6—Crohn's disease	6.17e-05	0.00119	CbGpPWpGaD
Gliclazide—ALB—Folate Metabolism—IL6—Crohn's disease	5.93e-05	0.00114	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—GPX4—Crohn's disease	5.92e-05	0.00114	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—SLC11A1—Crohn's disease	5.87e-05	0.00113	CbGpPWpGaD
Gliclazide—ALB—Selenium Micronutrient Network—TNF—Crohn's disease	5.84e-05	0.00113	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—RBX1—Crohn's disease	5.58e-05	0.00108	CbGpPWpGaD
Gliclazide—VEGFA—Cellular responses to stress—IL6—Crohn's disease	5.55e-05	0.00107	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PTGER4—Crohn's disease	5.43e-05	0.00105	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PLA2G4F—Crohn's disease	5.19e-05	0.001	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—ITGA4—Crohn's disease	4.94e-05	0.000952	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—UBE2D1—Crohn's disease	4.9e-05	0.000943	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—IL3—Crohn's disease	4.82e-05	0.000929	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—STAT3—Crohn's disease	4.81e-05	0.000927	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—RIPK2—Crohn's disease	4.75e-05	0.000915	CbGpPWpGaD
Gliclazide—ALB—Selenium Micronutrient Network—IL6—Crohn's disease	4.71e-05	0.000909	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—IL6—Crohn's disease	4.71e-05	0.000907	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—RASGRP1—Crohn's disease	4.66e-05	0.000898	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PLA2G4F—Crohn's disease	4.66e-05	0.000898	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—IL3—Crohn's disease	4.63e-05	0.000892	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—RASGRP1—Crohn's disease	4.48e-05	0.000863	CbGpPWpGaD
Gliclazide—ALB—Metabolism—MTMR3—Crohn's disease	4.41e-05	0.00085	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—JAK2—Crohn's disease	4.4e-05	0.000848	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PLA2G4F—Crohn's disease	4.25e-05	0.000819	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—TNF—Crohn's disease	4.16e-05	0.000802	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—SOCS1—Crohn's disease	4.06e-05	0.000782	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—MTMR3—Crohn's disease	3.96e-05	0.000763	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—MTMR3—Crohn's disease	3.61e-05	0.000696	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—SMAD3—Crohn's disease	3.5e-05	0.000675	CbGpPWpGaD
Gliclazide—ALB—Metabolism—FADS1—Crohn's disease	3.44e-05	0.000663	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—IL2RA—Crohn's disease	3.38e-05	0.000651	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—IL6—Crohn's disease	3.36e-05	0.000648	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—IL2RA—Crohn's disease	3.24e-05	0.000625	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GPX4—Crohn's disease	3.22e-05	0.00062	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GCKR—Crohn's disease	3.11e-05	0.000599	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—FADS1—Crohn's disease	3.09e-05	0.000595	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—ALB—Crohn's disease	3.07e-05	0.000591	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—ALB—Crohn's disease	2.98e-05	0.000574	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GPX4—Crohn's disease	2.89e-05	0.000557	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—FADS1—Crohn's disease	2.81e-05	0.000542	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GCKR—Crohn's disease	2.79e-05	0.000538	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PTGS2—Crohn's disease	2.68e-05	0.000517	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GPX4—Crohn's disease	2.64e-05	0.000508	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PTGS2—Crohn's disease	2.6e-05	0.000502	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GCKR—Crohn's disease	2.54e-05	0.00049	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—TYK2—Crohn's disease	2.28e-05	0.00044	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—JAK2—Crohn's disease	2.27e-05	0.000437	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—JAK2—Crohn's disease	2.18e-05	0.00042	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	1.99e-05	0.000384	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CXCL8—Crohn's disease	1.99e-05	0.000383	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	1.94e-05	0.000375	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	1.82e-05	0.000351	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	1.74e-05	0.000336	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—STAT3—Crohn's disease	1.6e-05	0.000308	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	1.59e-05	0.000307	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—IL6—Crohn's disease	1.12e-05	0.000215	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ALB—Crohn's disease	8.88e-06	0.000171	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PTGS2—Crohn's disease	8.66e-06	0.000167	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ALB—Crohn's disease	8.1e-06	0.000156	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PTGS2—Crohn's disease	7.77e-06	0.00015	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PTGS2—Crohn's disease	7.09e-06	0.000137	CbGpPWpGaD
